The rising prevalence in GLP-1 agonists for diabetes has generated a discussion about application forms : transdermal systems versus pills . Traditionally , GLP-1 treatments were exclusively available in https://matteoparm160889.verybigblog.com/39799676/glp-1-skin-applications-vs-pills-is-right-for-the-patient